New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
07:48 EDTPCYC, ABTPharmacyclics shares have 90% upside potential, says Deutsche Bank
Deutsche Bank believes shares of Pharmacyclics (PCYC) have 90% upside potential over the next 12 months following the recent pullback. Deutsche attributes to the recent pullback to fears around Abbott's (ABT) data for ABT199 at ASCO and weekly scripts that came in lower than some investor expectations. The firm has a Buy rating on Pharmacyclics with a $180 price target.
News For PCYC;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
08:29 EDTPCYCPharmacyclics price target raised to $253 from $204 at JMP Securities
Subscribe for More Information
January 13, 2015
12:48 EDTPCYCOn The Fly: Midday Wrap
Subscribe for More Information
10:08 EDTPCYCPharmacyclics gaps up, fades from earlier highs, levels to watch
Subscribe for More Information
10:00 EDTABTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:07 EDTPCYCOn The Fly: Pre-market Movers
HIGHER: Apple (AAPL), up 1.4% after Credit Suisse upgraded Apple to Outperform and raised its iPhone volume estimates again... Best Buy (BBY), up 2.8% after being upgraded to Buy from Neutral at Goldman... SunPower (SPWR), up 2.6% after being upgraded to Outperform at Credit Suisse... Alcoa (AA), up 2% after Q4 results beat expectations. RISING AFTER GUIDANCE: Pharmacyclics (PCYC), up 17.5%... CTI BioPharma (CTIC), up 8.3%... Emulex (ELX), up 15.5%... ARIAD (ARIA), up 2.6%. LOWER: ChannelAdvisor (ECOM), down 42% following preliminary fourth quarter revenue guidance and after receiving multiple analyst downgrades... Antares Pharma (ATRS), down 7.7% after the FDA recommended that the company create a larger safety database for its clinical development program for QuickShot Testosterone.
05:57 EDTABTAbbott downgraded to Hold from Buy at Jefferies
Subscribe for More Information
January 12, 2015
18:00 EDTPCYCPharmacyclics sees FY15 product revenue $1B for Imbruvica
Subscribe for More Information
17:58 EDTPCYCPharmacyclics sees FY14 product revenue $492M for Imbruvica
17:57 EDTPCYCPharmacyclics sees Q4 product revenue $185M for Imbruvica
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use